Study of low-dose capecitabine monotherapy for metastatic breast cancer.

  title={Study of low-dose capecitabine monotherapy for metastatic breast cancer.},
  author={Tetsuya Taguchi and Takahiro Nakayama and Norikazu Masuda and Katsuhide Yoshidome and Kenzou Akagi and Yukihiro Nishida and Yukinobu Yoshikawa and Nobuo Ogino and Chigusa Abe and Junichi Sakamoto and Shinzaburo Noguchi},
  volume={56 2},
BACKGROUND Capecitabine is an established therapy for metastatic breast cancer. In Japan, a 4 weekly regimen is often used, but data for this schedule in the first-line setting are lacking. METHODS Metastatic breast cancer patients who had received no chemotherapy for recurrent disease received capecitabine 825 mg/m(2) twice daily, on days 1-21 of a 28-day cycle until disease progression or unacceptable toxicity. The primary endpoint was response rate. RESULTS In 33 eligible patients… CONTINUE READING